A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT ID: NCT05330325
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
399 participants
INTERVENTIONAL
2022-08-10
2027-10-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Somapacitan
Participants will receive Somapacitan for 273 weeks
Somapacitan
Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
Norditropin®
Participants will receive Norditropin® for 52 weeks (main treatment period) and Somapacitan for 221 weeks (extension period)
Norditropin®
Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Somapacitan
Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
Norditropin®
Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. No prior exposure to growth promoting therapy, including but not limited to growth hormone, IGF-I and ghrelin analogues.
Applicable to children with SGA:
3. Born small for gestational age (birth length below -2 SDS OR birth weight below -2 SDS OR both) (according to national standards).
4. Prepubertal children:
1. Boys:
* Age above or equal to 2 years and 26 weeks and below 11.0 years at screening.
* Testis volume below 4 mL
2. Girls:
* Age above or equal to 2 years and 26 weeks and below 10.0 years at screening.
* Tanner stage 1 for breast development: No palpable glandular breast tissue)
5. Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention.
6. Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and sex according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.
7. Body Mass Index below the 95th percentile according to Centers for Disease Control and Prevention, Body Mass Index-for-age growth charts.
Applicable to girls with TS:
8. Confirmed diagnosis of TS by 30-cell (or more) lymphocyte chromosomal analysis.\*
9. Prepubertal girls:
* Age above or equal to 2 years and 26 weeks and below 10.0 years at screening.
* Tanner stage 1 for breast development: No palpable glandular breast tissue)
10. Impaired height defined as at least 2.0 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention.
11. Historical height measured 6-18 months prior to screening.
12. Thyroid hormone replacement therapy should be adequate and stable for at least 90 days prior to randomization, if applicable.
Applicable to children with NS:
13. Clinical diagnosis of NS according to van der Burgt score list
14. Prepubertal children:
1. Boys:
* Age above or equal to 2 years and 26 weeks and below 11.0 years at screening.
* Testis volume below 4 mL
2. Girls:
* Age above or equal to 2 years and 26 weeks and below 10.0 years at screening.
* Tanner stage 1 for breast development: No palpable glandular breast tissue)
15. Impaired height defined as at least 2.0 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention.
16. Historical height measured 6-18 months prior to screening.
17. Thyroid hormone replacement therapy should be adequate and stable for at least 90 days prior to randomization, if applicable.
Applicable to children with ISS:
18. Prepubertal children:
1. Boys:
* Age above or equal to 2 years and 26 weeks and below 11.0 years at screening.
* Testis volume below 4 mL
2. Girls:
* Age above or equal to 2 years and 26 weeks and below 10.0 years at screening.
* Tanner stage 1 for breast development: No palpable glandular breast tissue)
19. Bone age:
1. Boys:
* Bone age below or equal to 12 years.
* Bone age not delayed or advanced more than 2 years compared to chronological age.
2. Girls:
* Bone age below or equal to 11 years.
* Bone age not delayed or advanced more than 2 years compared to chronological age.
20. Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention.
21. Historical height measured 6-18 months prior to screening.
22. One normal GH secretion (GH peak above 7 ng/mL) during GH stimulation test performed within 18 months prior to screening or if such a test is not available for children with ISS, a test should be performed as part of the screening assessments and the result must be available prior to randomization.
* If a 30-cell count is not available for patients with TS, a test should be done, and results must be available prior to randomization.
Exclusion Criteria
2. Previous randomization into same sub-study in this study.
3. Receipt of any investigational medicinal product within 3 months before screening or participation in another clinical study at the time of randomization.
4. Children with suspected or confirmed growth hormone deficiency according to local practice.
5. laboratory of
1. fasting plasma glucose above or equal to 126 mg/dL (7.0 mmol/L) or
2. HbA1c above or equal to 6.5%.
6. Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
7. Children requiring inhaled glucocorticoid therapy at a dose greater than 400 µg/day of inhaled budesonide or equivalent (i.e., 250 µg/day for fluticasone propionate) for longer than 4 consecutive weeks within the last 12 months prior to screening.
8. Concomitant administration of other treatments that may have an effect on growth, e.g., but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder (ADHD).
9. Diagnosis of attention deficit hyperactivity disorder (ADHD).
10. History or known presence of any malignancy, intracranial tumour, or intracranial cyst.
11. History or known presence of active Hepatitis B or Hepatitis C (exceptions to this exclusion criterion is the presence of antibodies due to vaccination against Hepatitis B).
12. Any disorder, which in the investigator's opinion, might jeopardize participant's safety or compliance with the protocol.
13. The participant or the parent/legally acceptable representative is likely to be non-compliant in respect to study conduct, as judged by the investigator.
14. Current treatment with sex hormones or aromatase inhibitors.
15. Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements, such as, but not limited to:
1. Known family history of skeletal dysplasia.
2. Significant spinal abnormalities including but not limited to scoliosis, kyphosis and spina bifida variants.
3. Any other disorder/condition that can cause short stature such as, but not limited to, psychosocial deprivation, nutritional disorders, chronic systemic illness and chronic renal disease.
Applicable to children with SGA:
1. TS (including mosaicism).
2. NS.
3. Hormonal deficiencies.
4. Children who are small due to malnutrition defined as -2 standard deviations according to standards. 0¬-5 years: weight for height on World Health Organization Multicentre Growth Reference Study 2006. Above 5 years: World Health Organization 2007 Body Mass Index.
5. Known chromosomal aneuploidy or significant gene mutations causing medical 'syndromes' with short stature, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, skeletal dysplasias, abnormal SHOX gene analysis or absence of GH receptors.
Applicable to children with TS:
1. NS.
2. Mosaicism below 10%.
3. TS with Y-chromosome mosaicism where gonadectomy has not been performed.
4. NYHA class II or above or requiring medication for any heart condition.
5. Coeliac disease where participant is not stable on gluten free diet for the previous 12 months prior to screening.
Applicable to children with NS:
1. TS (including mosaicism).
2. Noonan-related disorders: Noonan syndrome with multiple lentigines (formerly called 'LEOPARD' syndrome), Noonan syndrome with loose anagen hair, cardiofaciocutaneous syndrome (CFC), Costello syndrome, neurofibromatosis type 1 (NF1) and Legius syndrome. Molecular genetic panel testing results must be available prior to randomisation to exclude these.
3. Coeliac disease where participant is not stable on gluten free diet for the previous 12 months prior to screening.
Applicable to children with ISS:
1. TS (including mosaicism).
2. NS.
3. Hormonal deficiencies.
4. Born small for gestational age (defined as birth length below -2 SDS OR birth weight below -2 SDS OR both) (according to national standards).
5. Known chromosomal aneuploidy or significant gene mutations causing medical 'syndromes' with short stature, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, skeletal dysplasias, abnormal SHOX gene analysis or absence of GH receptors.
2 Years
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Transparency dept. 2834
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ of AL at Birmingham_BRM
Birmingham, Alabama, United States
Children's Hospital Los Angeles - Endocrinology
Los Angeles, California, United States
Sutter Valley Med Fdt Ped Endo
Sacramento, California, United States
Rady Childrens Hosp San Diego
San Diego, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Rocky Mt Ped and Endo
Centennial, Colorado, United States
Ped Endo Assoc PC-G.V
Greenwood Village, Colorado, United States
Nemours/AI duPont Hosp-Chld
Wilmington, Delaware, United States
Childrens National Medical Ctr
Washington D.C., District of Columbia, United States
Nemours Chld Clnc Jacksonville
Jacksonville, Florida, United States
Atlanta Diabetes Associates
Atlanta, Georgia, United States
St. Luke's Children's Endo
Boise, Idaho, United States
Rocky Mt Clin Res, LLC
Idaho Falls, Idaho, United States
Riley Hosp for Child-Indiana U
Indianapolis, Indiana, United States
University OF Iowa
Iowa City, Iowa, United States
UMass Medical School
Worcester, Massachusetts, United States
Univ of Minnesota M.C.H.
Minneapolis, Minnesota, United States
Children's Minnesota
Saint Paul, Minnesota, United States
Univ of Mississippi Med Ctr
Jackson, Mississippi, United States
The Children's Mercy Hospital
Kansas City, Missouri, United States
Goryeb Children's Hospital
Morristown, New Jersey, United States
UBMD Peds-Div of Endo/Diabetes
Buffalo, New York, United States
NYU Langone Hospital-LI
Garden City, New York, United States
NYU Langone Hospital-LI
Mineola, New York, United States
WakeMed Childn Endo-Dbt_Raleig
Raleigh, North Carolina, United States
Akron Children's Hospital
Akron, Ohio, United States
CCHMC_Cinc
Cincinnati, Ohio, United States
Univ Oklahoma Sci Ctr OK City
Oklahoma City, Oklahoma, United States
UPMC Child Hosp-Pittsburgh
Pittsburgh, Pennsylvania, United States
UT Southwestern Med Cntr
Dallas, Texas, United States
Childrens' Hospital of Athens "Agia Sofia"
Goudi/Athens, , Greece
P & A Kyriakou Childrens' Hospital
Goudi/Athens, , Greece
General University of Patra - Paediatric Department
Pátrai, , Greece
'Ippokrateio' General Hospital of Thessaloniki
Thessaloniki, , Greece
Cook Children's Medical Center
Fort Worth, Texas, United States
Consano Clinical Research, LLC
Shavano Park, Texas, United States
University Of Virginia Hospitl
Charlottesville, Virginia, United States
MultiCare Inst for Res & Innov
Tacoma, Washington, United States
Marshfield Clinic
Marshfield, Wisconsin, United States
Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)
Linz, Upper Austria, Austria
Krankenhaus der Stadt Dornbirn
Dornbirn, , Austria
LKH St. Poelten, Kinder-und Jugendheilkunde
Sankt Pölten, , Austria
Salzkammergut-Klinikum Vöcklabruck
Vöcklabruck, , Austria
UZ Brussel
Brussels, , Belgium
Cliniques Universitaires Saint-Luc - Serv. Pédiatrie
Brussels, , Belgium
UZA - UZ Antwerpen - Kinderziekenhuis
Edegem, , Belgium
UZ Leuven - Kindergeneeskunde
Leuven, , Belgium
Centro de Diabetes Curitiba
Curitiba, Paraná, Brazil
Santa Casa Sao Paulo
São Paulo, São Paulo, Brazil
CPQuali Pesquisa Clínica Ltda
São Paulo, São Paulo, Brazil
Centro de Pesquisa Clínica do Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, São Paulo, Brazil
UMHAT "Dr. Georgi Stranski" Pleven
Pleven, , Bulgaria
UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
Plovdiv, , Bulgaria
SHATPD - Prof. Ivan Mitev EAD
Sofia, , Bulgaria
MHAT "Sveta Marina"
Varna, , Bulgaria
Children's Hosp-East Ontario
Ottawa, Ontario, Canada
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Liuzhou Maternity and Child Healthcare Hospital-Child Healthcare
Liuchow, Guangxi, China
Sanya Central Hospital (Hainan Third People's Hospital)-Pediatric
Sanya, Hainan, China
Henan Children's Hospital Zhengzhou Children's Hospital-Endocrine Genetics and Metabolism
Zhengzhou, Henan, China
Wuhan Children Hospital-Endocrine Genetics and Metabolism
Wuhan, Hubei, China
Wuhan Children Hospital
Wuhan, Hubei, China
Tongji Hospital, Tongji Medical College of HUST-Pediatric
Wuhan, Hubei, China
Hunan Children's Hospital-Child Health Center
Changsha, Hunan, China
The First Bethune Hospital of Jilin University-Pediatric
Changchun, Jilin, China
Shandong Provincial Hospital-Pediatric
Jinan, Shandong, China
Shanghai Children's Hospital -Endocrine Genetics and Metabolism
Shanghai, Shanghai Municipality, China
Shanghai Children's Medical Center-Endocrine Genetics and Metabolism
Shanghai, Shanghai Municipality, China
Chengdu Women's and Children's Central Hospital
Chengdu, Sichuan, China
KBC "Sestre Milosrdnice"
Zagreb, , Croatia
KBC Zagreb, Zavod za dječju endokrinologiju i dijabetes
Zagreb, , Croatia
HUS Uusi lastensairaala
Helsinki, , Finland
Centre Hospitalier Régional Universitaire d' Angers
Angers, , France
Centre Hospitalier Universitaire D'Angers-2
Angers, , France
Centre Hospitalier Universitaire de Bordeaux-Hopital Pellegrin
Bordeaux, , France
CHU Pellegrin
Bordeaux, , France
Ap-Hp-Hopital de Bicetre-1
Le Kremlin-Bicêtre, , France
Hopital de Bicetre_Le Kremlin-Bicetre
Le Kremlin-Bicêtre, , France
Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
Marseille, , France
Hopital de La Timone
Marseille Cédex 05, , France
Ap-Hp-Hopital Necker-2
Paris, , France
Hôpital Necker
Paris, , France
CHU de Toulouse
Toulouse, , France
Hopital Des Enfants
Toulouse, , France
Universitätsklinikum Bonn - Kinderklinik
Bonn, , Germany
Universitätsklinikum Erlangen - Kinder- und Jugendklinik
Erlangen, , Germany
Endokrinologikum Frankfurt
Frankfurt am Main, , Germany
Klinik für Allgemeine Pädiatrie und Neonatologie
Homburg, , Germany
Universitätsklinikum des Saarlandes - Pädiatrie und Neonatologie
Homburg, , Germany
U.G.H. "Attikon", Pediatric Endocrinology Outpatient Clinic
Athens, , Greece
"AHEPA" University General Hospital of Thessaloniki
Thessaloniki, , Greece
Ippokrateio Gen Hosp of Thessaloniki, 1st Pediatric Clinic
Thessaloniki, , Greece
Ippokrateio Gen Hosp of Thessaloniki, 1st Pediatric Clinic
Thessaloniki, , Greece
"AHEPA" University General Hospital of Thessaloniki
Thessaloniki, , Greece
Amrita Institute Of Medical Sciences & Research Centre
Kochi, Kerala, India
Jehangir Clinical Development Centre
Pune, Maharashtra, India
All India Institute of Medical Sciences
New Dehli, New Delhi, India
Cork University Hospital
Cork, , Ireland
CHI at Temple Street
Dublin, , Ireland
CHI Crumlin Dept of Endocrinology
Dublin, , Ireland
CHI Tallaght University Hospital
Dublin, , Ireland
Soroka MC - Pediatric Endocrinology
Beersheba, , Israel
Rambam MC - Department of Pediatrics A
Haifa, , Israel
Schneider MC - Endrocrinology and Diabetes
Petah Tikva, , Israel
Sheba MC - Pediatric endocrinology and adolescent diabetes clinics
Tel Litwinsky, , Israel
Shamir MC - Pediatric and Adolescents Endocrinology unit
Ẕerifin, , Israel
Ospedale San Raffaele S.r.l. - Unità Clinica Pediatria e neonatologia
Milan, Lombardy, Italy
IRCCS Meyer Firenze
Florence, , Italy
Ospedale Pediatrico Gaslini
Genova, , Italy
Ospedale San Raffaele UO di Pediatria e UO di Neonatologia
Milan, , Italy
Università degli Studi della Campania "L. Vanvitelli"
Napoli, , Italy
Bambin Gesù
Roma, , Italy
Ospedale Pediatrico Bambino Gesu
Roma, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCS
Rome, , Italy
Fukuoka Children's Hospital_Endocrinology and Metabolism
Fukuoka-shi, Fukuoka, , Japan
Fukuoka Children's Hospital
Fukuoka-shi, Fukuoka, , Japan
Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
Kobe-shi, Hyogo, , Japan
Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
Kyoto, , Japan
Nara Prefecture General Medical Center
Nara-shi, Nara, , Japan
Niigata University Medical & Dental Hospital_Pediatrics
Niigata-shi, Niigata, , Japan
Okayama Medical Center_Cardiology
Okayama-shi, Okayama, , Japan
Osaka City General Hospital, Pediatric Endocrinology and Me
Osaka, , Japan
Osaka Women's and Children's Hospital
Osaka, , Japan
Saitama Children's Medical Center, Endocrinorogy&Metabolism
Saitama-shi, Saitama, , Japan
Hokkaido University Hospital, Pediatrics
Sapporo, Hokkaido, , Japan
Hokkaido University Hospital_Pediatrics
Sapporo, Hokkaido, , Japan
Shizuoka Children's Hospital, Department of Diabetes and metabolism
Shizuoka-shi, Shizuoka, , Japan
Institute of Science Tokyo Hospital_Pediatrics
Tokyo, , Japan
Institute of Science Tokyo Hospital
Tokyo, , Japan
National Center for Child Health and Dev, Endo and Metabo
Tokyo, , Japan
Keio University Hospital, Pediatrics
Tokyo, , Japan
Fujita Health University Hospital, Pediatrics
Toyoake, Aichi, , Japan
Children's Clinical University Hospital
Riga, , Latvia
Hospital of Lithuanian University of Health Sciences Kauno klinikos
Kaunas, , Lithuania
Hospital Universiti Sains Malaysia_Kota Bharu, Kelantan
Kota Bharu, Kelantan, Malaysia
University Malaya Medical Centre
Kuala Lumpur, Kuala Lumpur, Malaysia
University Malaya Medical Centre
Lembah Pantai, Kuala Lumpur, Malaysia
University Technology MARA (UiTM) - Sg Buloh
Bandar Puncak Alam, Selangor, Malaysia
University Technology MARA (UiTM) - Puncak Alam
Bandar Puncak Alam Selangor Darul Ehsan, , Malaysia
Consultorio de Endocrinología y Pediatría
Puebla City, , Mexico
Erasmus MC
Rotterdam, , Netherlands
Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie
Rzeszów, Podkarpackie Voivodeship, Poland
UCK, Klinika Pediatrii, Diabetologii i Endokrynologii,
Gdansk, , Poland
Górnośląskie Centrum Zdrowia Dziecka Szpital Kliniczny Nr 6
Katowice, , Poland
Uniwer. Szpital Dzieciecy Klinika Endokry. Dzieci i Mlodzie
Krakow, , Poland
Uniwersytecki Szptal Dziecięcy w Krakowie
Krakow, , Poland
Klinika Endokrynologii i Chorób Metabolicznych
Lodz, , Poland
SPSK nr 1 im Prof. T Sokolowskiego
Szczecin, , Poland
Klinika Pediatrii SUM, SPSK nr 1 im. prof.S.Szyszko w Zabrzu_LOC#1
Zabrze, , Poland
SPSK nr 1 im. prof.S.Szyszko w Zabrzu
Zabrze, , Poland
Unidade Local de Saúde São José EPE- Hospital D. Estefânia
Lisbon, , Portugal
Centro Hospitalar Lisboa Norte
Lisbon, , Portugal
Unidade Local De Saude De Santa Maria E.P.E.
Lisbon, , Portugal
Unidade Local de Saúde de Santo António, E.P.E
Porto, , Portugal
Centro Hospitalar de Vila Nova de Gaia
Vila Nova de Gaia, , Portugal
King Faisal Specialist Hospital & Research Centre, Riyadh
Riyadh, , Saudi Arabia
National Guard Hospital
Riyadh, , Saudi Arabia
University Clinical Centre Nis
Niš, RS, Serbia
University Children's Hospital Tirsova
Belgrade, , Serbia
Institute for Mother and Child Health Care of Serbia
Belgrade, , Serbia
University Clinical Centre Kragujevac
Kragujevac, , Serbia
University Clinical Centre Nis
Niš, , Serbia
Institute for Health Care of Children and Adolescents
Novi Sad, , Serbia
PeK - Dept. of Paediatric Endocrinology, Diabetes and Metabolism
Ljubljana, , Slovenia
University Children's Hospital
Ljubljana, , Slovenia
Department of Peadiatrics CHBAH
Johannesburg, Gauteng, South Africa
Dr JC van Dyk's Rooms
Pretoria, Gauteng, South Africa
Dr Y Ganie's site
Mayville, KwaZulu-Natal, South Africa
Dr K Pillay's site
Westville, KwaZulu-Natal, South Africa
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
Chungnam National University Sejong Hospital
Sejong-si, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, A Coruña, Spain
Hospital Madrid Montepríncipe
Boadilla del Monte, Madrid, Spain
Hospital Sant Joan de Déu
Esplugues de Llobregat, , Spain
Med. Kinder- und Poliklinik
Bern, , Switzerland
Ramathibodi Hospital - Ped-Endo and Metabolism
Ratchathewi, Bangkok, Thailand
Ramathibodi Hospital - Ped-Endo and Metabolism
Bangkok, Ratchathewi, Thailand
King Chulalongkorn Memorial hospital-Ped-Endocrinology
Bangkok, , Thailand
King Chulalongkorn Memorial hospital_Ped-Endocrinology
Bangkok, , Thailand
Phramongkutklao Hospital_Ped-Endo_Pediatrics
Bangkok, , Thailand
PMK - Paediatrics Endocrinology Centre
Bangkok, , Thailand
Siriraj Hospital_Dept of Paediatrics
Bangkok, , Thailand
Maharaj Nakorn Chiang Mai Hospital_Pediatric Endocrinology
Chiang Mai, , Thailand
Srinagarind Hospital
Khon Kaen, , Thailand
Addenbrooke's Hospital_Cambridge
Cambridge, , United Kingdom
Hull Royal Infirmary
Hull, , United Kingdom
Alder Hey Children's Hospital
Liverpool, , United Kingdom
Evelina Children's Hospital - St Thomas'
London, , United Kingdom
Evelina London Children's Hospital
London, , United Kingdom
Royal Manchester Children's Hospital
Manchester, , United Kingdom
St George's Hospital
Tooting, , United Kingdom
St Georges Hospital
Tooting, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-005607-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
U1111-1270-0862
Identifier Type: OTHER
Identifier Source: secondary_id
NN8640-4467
Identifier Type: -
Identifier Source: org_study_id